Meeting
2019 ASCO Annual Meeting
Clinical and economic outcomes associated with sequential treatment in patients with advanced renal cell carcinoma (aRCC).
Authors
Meredith M. Regan
1 Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA
Meredith M. Regan , David F. McDermott , Michael B. Atkins , Apoorva Ambavane , Shuo Yang , Sumati Rao , M Dror Michaelson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4566)
DOI
10.1200/JCO.2019.37.15_suppl.4566
Abstract #
4566
Poster Bd #
392
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting.
First Author: Neil J. Shah
Poster
2021 Genitourinary Cancers Symposium
Treatment sequence after first-line nivolumab plus ipilimumab or sunitinib monotherapy in patients with metastatic renal cell carcinoma (mRCC) using real-world data.
First Author: Daniel M. Geynisman
Poster
2019 Genitourinary Cancers Symposium
Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
First Author: Amishi Yogesh Shah
Poster
2023 ASCO Genitourinary Cancers Symposium
CARINA interim analysis: A non-interventional study of real-world treatment sequencing and outcomes in patients with advanced renal cell carcinoma initiated on first-line checkpoint inhibitor-based combination therapy.
First Author: Paul D. Nathan